Simon Kung, MD

The study results suggest that patients with treatment-resistant depression who are on maintenance treatment require less frequent treatments with IV ketamine compared to IN esketamine.

In this study of patients with bipolar depression, 87.1% reached response and 74.2% reached remission with 6 weeks of rTMS.

Are ketamine and esketamine equally efficacious? This observational study compares the efficacy of subanesthetic intravenous ketamine with that of intranasal esketamine for treatment-resistant depression in a real-world clinical setting.